➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
McKinsey
Medtronic
Harvard Business School
Dow

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TREPROSTINIL

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Treprostinil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00060996 ↗ Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures Terminated United Therapeutics Phase 3 2003-02-01 The purpose of this study is to assess and compare the safety of continuous and daily subcutaneous Remodulin therapy in patients with critical limb ischemia (CLI) with no planned vascular interventional procedures; and to determine the effect of Remodulin on wound healing and treadmill walk distance.
NCT00147199 ↗ Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH) Completed United Therapeutics Phase 3 2005-06-01 This is a double-blind placebo-controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension. The primary outcome is the change in 6-minute walk distance from baseline to week 12.
NCT00325403 ↗ FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) Completed United Therapeutics Phase 3 2006-10-01 This study was an international, multicenter, randomized (2:1 active:placebo), double-blind, placebo-controlled study in subjects with PAH who were NOT currently receiving approved therapy for their PAH. Study visits occurred at 4 week intervals for 12 weeks (with an additional visit at Week 11) with the key measure of efficacy being the 6-minute walk test. Study procedures included routine blood tests, medical history, physical exams, disease evaluation, and exercise tests. Two optional substudies were also a part of FREEDOM-M at select centers - a hemodynamic substudy with a right heart catheterization at Baseline and Week 12 and a genetics and biomarkers substudy with blood samples collected at Baseline and Week 12. Patients who completed all assessments for 12 weeks were also eligible to enter an open-label, extension phase study (FREEDOM - EXT).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Treprostinil

Condition Name

Condition Name for Treprostinil
Intervention Trials
Pulmonary Arterial Hypertension 39
Pulmonary Hypertension 19
Interstitial Lung Disease 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Treprostinil
Intervention Trials
Hypertension 66
Familial Primary Pulmonary Hypertension 44
Hypertension, Pulmonary 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Treprostinil

Trials by Country

Trials by Country for Treprostinil
Location Trials
United States 480
India 25
Canada 23
Germany 22
France 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Treprostinil
Location Trials
California 32
Texas 30
New York 25
Pennsylvania 25
Ohio 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Treprostinil

Clinical Trial Phase

Clinical Trial Phase for Treprostinil
Clinical Trial Phase Trials
Phase 4 14
Phase 3 27
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Treprostinil
Clinical Trial Phase Trials
Completed 28
Recruiting 21
Not yet recruiting 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Treprostinil

Sponsor Name

Sponsor Name for Treprostinil
Sponsor Trials
United Therapeutics 59
University Hospital, Grenoble 4
Lung Biotechnology PBC 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Treprostinil
Sponsor Trials
Industry 77
Other 50
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Boehringer Ingelheim
Harvard Business School
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.